NCT07370194 Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil
| NCT ID | NCT07370194 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Hyperkalemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,215 participants |
| Start Date | 2026-03-31 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,215 participants in total. It began in 2026-03-31 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a descriptive, retrospective study involving patients from private cardiology, nephrology, and dialysis clinics in Brazil who participated in the National Hyperkalaemia Diagnosis Campaign. The study used anonymised data from the Hi Technologies Ltda. database. The objective was to estimate and characterise the prevalence of hyperkalaemia (HK), as well as to analyse the demographic profile, clinical characteristics, risk factors and treatment patterns associated with total blood potassium levels.
Eligibility Criteria
Inclusion Criteria: * Participants aged 18 years or older; Pre-existing comorbidities, including: o Heart failure (regardless of phenotype); o Chronic kidney disease (any stage); o Diabetes mellitus; o Systemic arterial hypertension. Exclusion Criteria: * Diagnosis of advanced malignant neoplasm undergoing palliative treatment; Other advanced diseases with a life expectancy of less than one year; Patients with no information on risk factors for hyperkalaemia (HK).
Contact & Investigator
Bernardo Montesanti de Almeida, Medical
PRINCIPAL INVESTIGATOR
Hi Tecnologies
Frequently Asked Questions
Who can join the NCT07370194 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperkalemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07370194 currently recruiting?
Yes, NCT07370194 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07370194 trial being conducted?
This trial is being conducted at Curitiba, Brazil.
Who is sponsoring the NCT07370194 clinical trial?
NCT07370194 is sponsored by AstraZeneca. The principal investigator is Bernardo Montesanti de Almeida, Medical at Hi Tecnologies. The trial plans to enroll 6,215 participants.